[144] Immuneering Corp SEC Filing

Rhea-AI Filing Summary

Immuneering Corp (IMRX) filed a Form 144 reporting a proposed sale of 14,000 Class A shares through Fidelity Brokerage Services LLC on the NASDAQ with an approximate sale date of 09/23/2025 and an aggregate market value of $136,080.00. The filing shows the shares were acquired in two open-market purchases: 8,000 shares on 03/18/2024 (paid in cash) and 6,000 shares on 03/15/2022 (paid in cash). The filer attests there is no material nonpublic information about the issuer and no securities were sold by the filer in the past three months according to the form.

Insights

Securities Analyst

TL;DR: Routine insider notice of planned sale; modest size relative to total outstanding shares.

The Form 144 discloses a planned open-market sale of 14,000 Class A shares via a major broker with an indicated aggregate market value of $136,080.00 and an approximate sale date of 09/23/2025. The shares were acquired in open-market purchases in 2022 and 2024 and were paid for in cash, which aligns with typical insider liquidity events. The filer also certifies no material nonpublic information is known. From a market-impact perspective this is a routine disclosure; the form does not provide broader context about the filer’s holdings or motivations.

Compliance Officer

TL;DR: Filing meets Rule 144 notice elements; contains standard representations and broker details.

The submission includes required broker identification (Fidelity Brokerage Services LLC) and the seller's acquisition history for the reported lots, with cash payment dates specified. The signature block includes the Rule 144 attestation regarding material nonpublic information and a warning about false statements. There are no reported sales in the preceding three months. From a regulatory-compliance perspective, the form appears complete for a Rule 144 notice based on the information provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 245 Summer Street Boston MA 02110	14000	136080.00	36318877	09/23/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	03/18/2024	Open Market Purchase	N/A			8000	03/18/2024	Cash
Class A	03/15/2022	open market Purchase	N/A			6000	03/15/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Immuneering Corp's (IMRX) Form 144 report?

The Form 144 reports a proposed sale of 14,000 Class A shares with an aggregate market value of $136,080.00, to be sold through Fidelity on NASDAQ around 09/23/2025.

When and how were the shares being sold on IMRX acquired?

8,000 shares were acquired in an open-market purchase on 03/18/2024 (cash) and 6,000 shares on 03/15/2022 (cash).

Does the filing indicate any securities sold in the past three months by the filer?

No. The form states "Nothing to Report" for securities sold during the past three months.

Which broker and exchange are named in the Form 144 for IMRX?

Fidelity Brokerage Services LLC, 245 Summer Street Boston MA 02110; the securities are to be sold on NASDAQ.

Does the filer assert knowledge of any material nonpublic information about IMRX?

The filer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.